Appili Therapeutics Inc remains stable despite recent market performance.
This week, Appili Therapeutics Inc (APLI.TO) closed at C$0.01, maintaining its value with no significant fluctuations. The company recently reported its financial and operational results for the fiscal year 2026, showing progress in its commercial-stage programs and securing US$40 million in non-dilutive funding.
Investor takeaway: Investors should note the company's recent funding successes and operational updates, which may impact future performance despite current stock price stagnation.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.19
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
357.9%
Annualized
90-Day Vol
278.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.03 |
| 60 trading days | C$0.01 | C$0.00 – C$0.05 |
| 90 trading days | C$0.01 | C$0.00 – C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Appili's stock has a 52-week range of C$0.01 to C$0.04.
The stock is currently trading at the lower end of its 52-week range, indicating a lack of upward momentum in the market.
Bull case
The recent US$40 million funding from NIAID and the growing adoption of LIKMEZ® could enhance the company's operational capabilities and market presence, potentially leading to growth.
Bear case
Despite the funding, Appili's stock has dropped 60% year-to-date. Current financial metrics, including a negative profit margin and return on equity, may raise concerns for investors.
Recent Price Action
Advertisement
Appili Therapeutics Inc (APLI.TO) has remained unchanged this week, closing at C$0.01. Year-to-date, the stock has seen a decline of 60%, indicating a challenging year for investors.
Company News
This week, Appili announced its financial and operational results for the fiscal year ended March 31, 2026. The company highlighted its progress in commercial-stage programs and the successful acquisition of US$40 million in non-dilutive funding, which will support its ongoing initiatives, including the development of LIKMEZ® and other infectious disease programs.
Technical Picture
From a technical standpoint, Appili's stock is currently trading below both its 50-day moving average of C$0.01 and its 200-day moving average of C$0.02, suggesting bearish sentiment in the market. The stock has a beta of -0.19, indicating lower volatility compared to the broader market. With a 52-week range of C$0.01 to C$0.04, the current price reflects a lack of momentum, trading at the bottom of this range. The latest trading volume was 102,300 shares, which is 1.33 times the 20-day average volume of 76,761 shares.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
